Vandetanib versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR)
Purpose Vandetanib is a once-daily oral inhibitor of vascular endothelial growth factor receptor, epidermal growth factor receptor (EGFR), and RET signaling. This placebo-controlled trial assessed whether vandetanib conferred an overall survival benefit in patients with advanced non-small-cell lung...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
April 2012
|
| In: |
Journal of clinical oncology
Year: 2012, Volume: 30, Issue: 10, Pages: 1114-1121 |
| ISSN: | 1527-7755 |
| DOI: | 10.1200/JCO.2011.36.1709 |
| Online Access: | Verlag, Volltext: http://dx.doi.org/10.1200/JCO.2011.36.1709 Verlag, Volltext: http://ascopubs.org/doi/abs/10.1200/JCO.2011.36.1709 
|
| Author Notes: | Jin Soo Lee, Vera Hirsh, Keunchil Park, Shukui Qin, Cesar R. Blajman, Reury-Perng Perng, Yuh-Min Chen, Laura Emerson, Peter Langmuir, and Christian Manegold |
| Summary: | Purpose Vandetanib is a once-daily oral inhibitor of vascular endothelial growth factor receptor, epidermal growth factor receptor (EGFR), and RET signaling. This placebo-controlled trial assessed whether vandetanib conferred an overall survival benefit in patients with advanced non-small-cell lung cancer (NSCLC) after prior treatment with an EGFR tyrosine kinase inhibitor and one or two chemotherapy regimens. |
|---|---|
| Item Description: | Gesehen am 11.04.2018 |
| Physical Description: | Online Resource |
| ISSN: | 1527-7755 |
| DOI: | 10.1200/JCO.2011.36.1709 |